The Ledger

CVS

CVS Health CorpHealth Careinsider_universe

Last close $103.70Jun 28, 2026

Day −0.61%

Currently held

Agent 6 — Options Momentumlong
1 contracts · CALL $105 exp Jul 30, 2026 · entry $3.14
+$21.91 unrealized

Everything we've seen

·Jun 29, 3:45 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 3:30 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 3:15 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 3:01 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 2:45 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 2:30 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 2:15 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 2:00 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 1:45 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 1:30 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 1:15 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 1:00 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 12:45 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 12:30 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 12:15 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 12:15 PMstreamnews
CVS Health Corporation (CVS) Hits Fresh High: Is There Still Room to Run?
CVS Health (CVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
·Jun 29, 12:00 PMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 11:45 AMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 11:30 AMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 11:15 AMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 11:01 AMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 10:45 AMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 10:30 AMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 10:15 AMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
·Jun 29, 10:15 AMstreamnews
2 Healthcare Stocks with Competitive Advantages and 1 Facing Challenges
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 12.4% gain over the past six months, beating the S&P 500 by 5.6 percentage points.
·Jun 29, 10:15 AMstreamnews
How CVS Health Is Helping America Celebrate Its 250th Anniversary
Originally published on CVS Health Company Newsroom NORTHAMPTON, MA / ACCESS Newswire / June 29, 2026 / As the nation prepares to celebrate its 250th anniversary, CVS Health is stepping into a unique role as the Official Memory Maker of America250 ...
·Jun 29, 10:01 AMstreamnews
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
❖Jun 29, 9:15 AMnewsvia finnhub
CVS Health Corporation (CVS) Hits Fresh High: Is There Still Room to Run?
CVS Health (CVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
❖Jun 29, 9:00 AMnewsvia finnhub
How CVS Health Is Helping America Celebrate Its 250th Anniversary
Originally published on CVS Health Company Newsroom NORTHAMPTON, MA / ACCESS Newswire / June 29, 2026 / As the nation prepares to celebrate its 250th anniversary, CVS Health is stepping into a unique role as the Official Memory Maker of America250 ...
❖Jun 29, 8:50 AMnewsvia finnhub
2 Healthcare Stocks with Competitive Advantages and 1 Facing Challenges
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 12.4% gain over the past six months, beating the S&P 500 by 5.6 percentage points.
❖Jun 29, 7:20 AMnewsvia finnhub
Magic Formula Showdown: Why CVS Beats Qualcomm and Valero for Retirees
Joel Greenblatt's Magic Formula ranks stocks on earnings yield and return on capital, but for retirees those two numbers can point straight toward disaster. Three stocks cleared the screen, and only one survives when income reliability and volatility enter the equation.
❖Jun 27, 12:50 AMnewsvia finnhub
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
The stock is already up 30% this year.
❖Jun 26, 7:11 AMnewsvia finnhub
TD Cowen Reaffirms Buy Rating on Salesforce (CRM) as AI Momentum and Agentforce Drive Growth
Salesforce Inc. (NYSE:CRM) ranks among the best set-it-and-forget-it stocks to buy right now. On June 12, TD Cowen reaffirmed its $240 price objective and Buy rating on Salesforce Inc. (NYSE:CRM). The update came after the firm hosted an investor dinner with new IR Senior Director Lauren O’Brien and the Vice President of Investor Relations, Valmik […]
❖Jun 26, 6:10 AMnewsvia finnhub
CFOs On the Move: Week ending June 26
Pfizer's CFO joins Nike, Wendy's hires Potbelly Sandwiches' CFO, Airwallex's new CFO boomerangs back to the company and more.
❖Jun 25, 5:08 PMnewsvia finnhub
CVS Health (CVS) Stock Sees Modest Fair Value Lift As GLP 1 And Margins Help
CVS Health’s implied fair value has been updated from US$102.85 to US$105.38 per share, signaling a modest reset in how analysts are framing the stock. Behind this move, recent research highlights stronger engagement potential from GLP 1 programs, improving sentiment toward managed care, and an earnings story that some bullish analysts view as supported by margin recovery and policy visibility, even as more cautious voices flag ongoing risks. Keep reading to see what is driving this evolving...
❖Jun 25, 4:30 PMnewsvia finnhub
[Latest] Global Healthcare Discount Plan Market Size/Share Worth USD 48.37 Billion by 2035 at a 8.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Healthcare Discount Plan Market size & share revenue was valued at approximately USD 18.64 Billion in 2025 and is expected to reach USD 20.84 Billion in 2026 and is expected to reach around USD 48.37 Billion by 2035, at a CAGR of 8.8% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are GoodRx Holdings Inc.,
❖Jun 25, 4:08 PMnewsvia finnhub
CVS Health (CVS) Faces Florida Probe Into Caremark Over Pharmacy Competition
Florida's Attorney General has opened an investigation into CVS Health's (NYSE:CVS) Caremark pharmacy benefit manager for alleged anticompetitive practices. The probe focuses on claims of steering patients, preferential reimbursement rates, and burdensome audits that may disadvantage independent pharmacies. The investigation centers on Caremark's role in managing prescription drug benefits and its interactions with pharmacies across Florida. CVS Health sits at the intersection of retail...
❖Jun 25, 3:46 PMnewsvia finnhub
Friday's big stock stories: What’s likely to move the market in the next trading session
On Thursday, the Nasdaq Composite fell for a fourth straight day as shares of Apple and Microsoft slid.
✓Jun 25, 2:20 PMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on CVS — 5-day return 5.06% with close above 20-day MA ($97.43). IV 25.4%. Sized 1 contract(s) at $3.14 premium.
?Jun 25, 11:16 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CVS is up 2.36% intraday with 270 minutes remaining, suggesting this move initiated early and has had time to develop. The move represents meaningful institutional flow. No headline catalyst is identifiable, which is common — this may be sector rotation, options flow, or technical breakout above $101-102 resistance. The macro context shows 10Y inflation expectations (T10YIE) running 2.4σ below trend, which is modestly favorable for defensive/healthcare names like CVS as it signals a lower-rate, lower-inflation environment that reduces pressure on their debt load and consumer-facing pharmacy business. However, there are no strong conviction signals to push this above 0.65: no confirming news, no sector catalyst mentioned, and CVS has had a volatile 2025-2026 period with structural headwinds (PBM reform risk, Aetna losses). With 270 minutes left there is ample time for continuation, but the absence of any catalyst narrative means this could fade if it was driven by a single large order that is now complete. Assigning modest continuation probability above the 0.5 threshold given the size of the move, time remaining, and supportive macro backdrop, but not high conviction.
!Jun 25, 11:16 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CVS is up 2.36% intraday with 270 minutes remaining, suggesting this move initiated early and has had time to develop. The move represents meaningful institutional flow. No headline catalyst is identifiable, which is common — this may be sector rotation, options flow, or technical breakout above $101-102 resistance. The macro context shows 10Y inflation expectations (T10YIE) running 2.4σ below trend, which is modestly favorable for defensive/healthcare names like CVS as it signals a lower-rate, lower-inflation environment that reduces pressure on their debt load and consumer-facing pharmacy business. However, there are no strong conviction signals to push this above 0.65: no confirming news, no sector catalyst mentioned, and CVS has had a volatile 2025-2026 period with structural headwinds (PBM reform risk, Aetna losses). With 270 minutes left there is ample time for continuation, but the absence of any catalyst narrative means this could fade if it was driven by a single large order that is now complete. Assigning modest continuation probability above the 0.5 threshold given the size of the move, time remaining, and supportive macro backdrop, but not high conviction.
❖Jun 25, 10:19 AMnewsvia finnhub
Can Cigna's Expansion Beyond Health Insurance Fuel Long-Term Growth?
CI is evolving beyond traditional insurance, using AI, specialty pharmacy and healthcare services to drive growth and sharpen its business focus.
❖Jun 25, 10:04 AMnewsvia finnhub
ARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January
ARS Pharmaceuticals stock collapsed Thursday after CVS Caremark declined to add its epinephrine spray, Neffy, to its formulary.
?Jun 25, 9:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CVS is up 1.70% today, a moderate but meaningful move suggesting real institutional flow. There are no headlines to explain the move, which is common — the absence of news doesn't disqualify continuation. The macro context shows 10-year inflation expectations (T10YIE) printing 2.4σ below trend, which is a tailwind for long-duration sensitive sectors and broadly supportive of defensive/healthcare names like CVS, as lower inflation expectations can ease pressure on margins and support valuation multiples. However, a 1.70% move is on the lower end of 'high conviction' signals — it's notable but not dramatic. With 360 minutes remaining (essentially a full session still ahead), there is ample time for the move to extend or fade, which cuts both ways. No reversal pattern is evident from the data provided. On balance, the modest size of the move plus supportive macro backdrop and full day remaining supports a mild continuation bias, but not a strong one. Setting probability at 0.54 — a lean toward continuation without strong conviction.
!Jun 25, 9:45 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CVS is up 1.70% today, a moderate but meaningful move suggesting real institutional flow. There are no headlines to explain the move, which is common — the absence of news doesn't disqualify continuation. The macro context shows 10-year inflation expectations (T10YIE) printing 2.4σ below trend, which is a tailwind for long-duration sensitive sectors and broadly supportive of defensive/healthcare names like CVS, as lower inflation expectations can ease pressure on margins and support valuation multiples. However, a 1.70% move is on the lower end of 'high conviction' signals — it's notable but not dramatic. With 360 minutes remaining (essentially a full session still ahead), there is ample time for the move to extend or fade, which cuts both ways. No reversal pattern is evident from the data provided. On balance, the modest size of the move plus supportive macro backdrop and full day remaining supports a mild continuation bias, but not a strong one. Setting probability at 0.54 — a lean toward continuation without strong conviction.
❖Jun 25, 9:40 AMnewsvia finnhub
Nike Joins Alphabet, Walmart in Hiring a CFO From the Outside
(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a
❖Jun 25, 9:00 AMnewsvia finnhub
CVS Health Foundation invests $1 million in Hartford nonprofits tackling community health needs
The CVS Health Foundation is investing $1 million in grants through its Hometown Fund to 20 organizations that are making a difference for the Greater Hartford area every day. This year, Hometown Fund grants will support local nonprofits working to increase access to health care, address food insecurity, expand availability of stable housing and increase access to critical community services across the Greater Hartford area.
❖Jun 25, 9:00 AMnewsvia finnhub
CVS Health Foundation invests $1 million in Rhode Island nonprofits tackling community health needs
The CVS Health Foundation is investing $1 million in grants through its Hometown Fund to 20 organizations that are making a difference for Rhode Islanders every day. This year, Hometown Fund grants will support local nonprofits working to increase access to health care, address food insecurity, expand availability of stable housing and improve community health across the state.
❖Jun 24, 9:41 AMnewsvia finnhub
Can a Former Pfizer Executive Catalyze Nike’s Sluggish Turnaround?
Nike names David Denton, a former Pfizer and CVS Health executive, as its next chief financial officer. The company also provides updated guidance.
❖Jun 24, 9:00 AMnewsvia finnhub
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
❖Jun 24, 8:45 AMnewsvia finnhub
Nike’s surprise CFO change ‘another tangible signal’ of turnaround progress
While analysts acknowledged incoming finance chief David Denton’s credentials, they also flagged his lack of activewear experience.
❖Jun 24, 8:35 AMnewsvia finnhub
Nike names Pfizer CFO David Denton to replace Matthew Friend
David Denton, who has led Pfizer's finances since 2022, will take over as Nike's chief financial officer on Aug. 17
❖Jun 24, 8:09 AMnewsvia finnhub
Nike’s New Finance Chief Isn’t a Retail Insider—He’s Coming From Pfizer
Nike names David Denton, a former Pfizer and CVS Health executive, as its next chief financial officer, and provides updated guidance.
❖Jun 24, 7:01 AMnewsvia finnhub
Florida launches probe into CVS for alleged anticompetitive pharmacy practices
The investigation by Florida’s attorney general comes as states look to check pharmacy benefit managers for allegedly driving up drug costs.
❖Jun 23, 6:01 PMnewsvia finnhub
NKE Stock Gains 2% After-Hours As Nike Names New CFO, Reaffirms Outlook — Retail Calls Leadership Transition ‘Promising’
Nike announced a CFO transition and said fourth-quarter results remain on track, excluding a one-time tariff refund benefit.
❖Jun 23, 5:33 PMnewsvia finnhub
Florida Attorney General Issues Subpoena to CVS Health in Pharmacy Probe
Florida’s attorney general says he is examining whether CVS’s pharmacy benefit manager steers patients to its own pharmacies.
❖Jun 23, 10:34 AMnewsvia finnhub
CVS Health Subpoenaed By Florida Attorney General Uthmeier Over Alleged Anticompetitive Practices
https://www.myfloridalegal.com/newsrelease/attorney-general-james-uthmeier-issues-subpoena-cvs-health-corporation-and-caremark
❖Jun 23, 9:00 AMnewsvia finnhub
CVS Health: Thank You! Mews at St. Mary Grand Opening - Williamstown, NJ
NORTHAMPTON, MA / ACCESS Newswire / June 23, 2026 / Last week, we proudly celebrated the Grand Opening and Building Dedication of Mews at St. Mary in Williamstown, NJ, alongside our amazing colleagues, local leaders, community organizations, development ...
❖Jun 23, 4:56 AMnewsvia finnhub
B of A Securities Maintains Buy on CVS Health, Raises Price Target to $110
B of A Securities analyst Allen Lutz maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $100 to $110.
❖Jun 23, 4:35 AMnewsvia finnhub
CVS Health (CVS) Under the Microscope After Recent Healthcare Report
CVS Health Corporation (NYSE:CVS) is one of the 10 Cheap Jim Cramer Stocks to Invest In Right Now. The New York Times, in an article published on June 11, 2026, pointed to two federal reports from the Department of Health and Human Services and stated that CVS Health Corporation (NYSE:CVS) and other major Medicare Advantage […]
?Jun 22, 3:25 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CVS has made a meaningful 3.31% intraday move, which signals real institutional flow. However, with only 20 minutes remaining until the forced close at 3:45 PM ET, the time window is critically short. A +3% profit target from current levels would require reaching ~$104.63, which is unlikely to be achieved in 20 minutes absent a catalyst. The macro context (T5YIE 1.5σ below trend) is mildly disinflationary and not particularly supportive for healthcare/pharmacy retail names. There are no recent news headlines to sustain or explain the move, and with this much of the session already behind us, late-session profit-taking and mean reversion pressure are more likely than a further squeeze. The risk/reward of chasing a 3.31% move with only 20 minutes left and no visible catalyst does not clear the threshold — the time constraint alone is the dominant factor here.
!Jun 22, 3:25 PMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
CVS has made a meaningful 3.31% intraday move, which signals real institutional flow. However, with only 20 minutes remaining until the forced close at 3:45 PM ET, the time window is critically short. A +3% profit target from current levels would require reaching ~$104.63, which is unlikely to be achieved in 20 minutes absent a catalyst. The macro context (T5YIE 1.5σ below trend) is mildly disinflationary and not particularly supportive for healthcare/pharmacy retail names. There are no recent news headlines to sustain or explain the move, and with this much of the session already behind us, late-session profit-taking and mean reversion pressure are more likely than a further squeeze. The risk/reward of chasing a 3.31% move with only 20 minutes left and no visible catalyst does not clear the threshold — the time constraint alone is the dominant factor here.
?Jun 22, 11:36 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CVS is up ~4% intraday with no attributable headline, suggesting this is likely driven by institutional flow, a sector rotation, or a delayed reaction to something like earnings guidance, analyst action, or broader healthcare sector movement. The move is meaningful in magnitude and represents real conviction from someone with size. However, several factors temper enthusiasm: (1) No supporting news catalyst is visible, which makes it harder to assess whether the catalyst is durable or fully priced in; (2) With 250 minutes remaining there is ample time but also ample time for a fade if this was a gap-and-exhaust pattern; (3) The macro context (T5YIE 1.5σ below trend) signals a low inflation expectations regime, which is modestly supportive for rate-sensitive defensive sectors like healthcare/pharmacy, but CVS specifically is not a direct TIPS/Gold/Energy play so macro tailwind is indirect at best; (4) A ~4% move in a large-cap defensive name like CVS is unusual and could attract profit-taking into the close. Balancing the base-rate momentum case (moves of this size have mild continuation tendency) against the absence of a clear catalyst and the potential for mean-reversion in a slow-news environment, a modest continuation probability just above neutral is appropriate.
!Jun 22, 11:36 AMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
CVS is up ~4% intraday with no attributable headline, suggesting this is likely driven by institutional flow, a sector rotation, or a delayed reaction to something like earnings guidance, analyst action, or broader healthcare sector movement. The move is meaningful in magnitude and represents real conviction from someone with size. However, several factors temper enthusiasm: (1) No supporting news catalyst is visible, which makes it harder to assess whether the catalyst is durable or fully priced in; (2) With 250 minutes remaining there is ample time but also ample time for a fade if this was a gap-and-exhaust pattern; (3) The macro context (T5YIE 1.5σ below trend) signals a low inflation expectations regime, which is modestly supportive for rate-sensitive defensive sectors like healthcare/pharmacy, but CVS specifically is not a direct TIPS/Gold/Energy play so macro tailwind is indirect at best; (4) A ~4% move in a large-cap defensive name like CVS is unusual and could attract profit-taking into the close. Balancing the base-rate momentum case (moves of this size have mild continuation tendency) against the absence of a clear catalyst and the potential for mean-reversion in a slow-news environment, a modest continuation probability just above neutral is appropriate.
❖Jun 15, 3:39 AMnewsvia finnhub
Zacks.com featured highlights include StoneCo, USANA Health, Strategic Education, Nexa Resources and CVS
STNE, USNA, STRA, NEXA and CVS are highlighted as low price-to-book stocks with solid growth projections and strong value scores.
❖Jun 15, 1:27 AMnewsvia finnhub
Is CVS Health (CVS) One of Billionaire Larry Robbins’ 10 Dividend Stock Picks?
CVS Health Corporation (NYSE:CVS) is included among Billionaire Larry Robbins’ 10 Dividend Stock Picks. On June 4, Morgan Stanley raised its price recommendation on CVS Health Corporation (NYSE:CVS) to $111 from $106. It reiterated an Overweight rating on the shares. The analyst noted that managed care stocks have been “grinding higher” as signs of softer […]
▣Jun 14, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 100 @ $4.72 (+$112.51)
Stop: premium $4.72 ≤ trailing floor $4.90 (peak $6.54 × 0.75)
❖Jun 14, 3:10 PMnewsvia finnhub
HHS Scrutiny And Primary Care Expansion Shape CVS Health Investor Questions
The HHS Office of Inspector General highlights CVS Health's Medicare Advantage arm for high denial rates in post acute care, raising questions about senior access to services. CVS Health advances its primary care partnership with Mass General Brigham after clearing a key regulatory hurdle. Both developments focus attention on NYSE:CVS and its approach to care delivery, costs, and regulatory oversight. These updates arrive while CVS Health, trading at $101.96, has seen the stock up 6.3% over...
❖Jun 14, 1:38 AMnewsvia finnhub
Mizuho Raises CVS Health (CVS) Price Target on More Stable Policy Environment
With an annual dividend yield of 2.65%, CVS Health Corporation (NYSE:CVS) is included among the 12 High Yield Fortune 500 Stocks to Buy Now. America’s leading health solutions company, CVS Health Corporation (NYSE:CVS), provides advanced health care from pharmacy services and health plans to health and wellness. On June 8, Mizuho upped its price target on […]
❖Jun 13, 12:33 PMnewsvia finnhub
Closed Rite Aid stores get surprising retail replacement
When Rite Aid, a major pharmacy retailer, filed for Chapter 11 bankruptcy a second time in 2025, it led to the shuttering of its 1,250 locations. Over time, many were sold to competitors like CVS and Walgreens, and some spaces were taken up by retailers such as Kroger and Albertsons. But some ...
❖Jun 13, 9:30 AMnewsvia finnhub
3 Ridiculously Cheap Healthcare Stocks to Buy in June
Healthcare has spent 2026 on the sidelines while the rest of the market does the heavy lifting. The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is down around 1% year to date even after a 6% one-month bounce. That stagnation has left a handful of high-margin operators trading at forward multiples that look out of ... 3 Ridiculously Cheap Healthcare Stocks to Buy in June
❖Jun 12, 1:18 PMnewsvia finnhub
MOH Wins Illinois Medicaid Contract, Reinforcing Long-Term Stability
Molina Healthcare secures an Illinois Medicaid managed care contract starting in 2027, reinforcing its position in a key market and supporting long-term growth.
❖Jun 12, 12:58 PMnewsvia finnhub
Leaving Las Vegas: How to Beat the House as the Stock Market Turns Into a Casino
Here’s a 30,000-foot view on practical ways to protect your investing capital and gain a real edge over the house in a stock market designed to keep you glued to the slots instead of growing your wealth.
❖Jun 12, 12:36 PMnewsvia finnhub
UnitedHealth, FTC reach proposed settlement in insulin case
The tentative deal comes months after CVS Health reached a proposed settlement in the lawsuit alleging major pharmacy benefit managers are inflating insulin costs.
❖Jun 12, 11:17 AMnewsvia finnhub
CVS Health (CVS): Buy, Sell, or Hold Post Q1 Earnings?
Over the past six months, CVS Health has been a great trade, beating the S&P 500 by 20%. Its stock price has climbed to $100.39, representing a healthy 26.4% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
❖Jun 12, 11:10 AMnewsvia finnhub
Is CVS (CVS) Using GLP-1 Access and AI Tools to Redefine Its Healthcare Moat?
In recent days, CVS Health expanded access to GLP-1 weight management drugs, reintroducing Zepbound and easing restrictions on new oral therapies, while also advancing AI-driven tools across its pharmacy, insurance and care delivery platforms. Together, these moves highlight how CVS is trying to pair broader drug affordability with technology-led efficiencies in care delivery and operations. Next, we’ll examine how CVS’s broader GLP-1 coverage and affordability push could influence the...
?Jun 12, 10:50 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CVS is up 1.65% today with no attributable headline, suggesting the move is flow/technical in nature rather than news-driven. The magnitude is modest but real — below the 2-5% 'high conviction' threshold, so it represents meaningful but not overwhelming buying pressure. Macro context shows a flattening yield curve (T10Y2Y at 2.1σ below trend), which is moderately supportive for defensives like CVS — a healthcare/pharmacy name that tends to benefit in risk-off or flattening environments. No reversal signals are evident from the data provided. With 295 minutes remaining (nearly a full session left), there is ample time for the move to continue or extend. However, the absence of a catalyst and the sub-2% magnitude temper conviction — this is ordinary momentum without a clear accelerant. Assigning a modest continuation probability above the threshold: the macro backdrop is a mild tailwind, time is sufficient, and there is no reason to expect a fade. Taking the trade at baseline momentum probability.
!Jun 12, 10:50 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CVS is up 1.65% today with no attributable headline, suggesting the move is flow/technical in nature rather than news-driven. The magnitude is modest but real — below the 2-5% 'high conviction' threshold, so it represents meaningful but not overwhelming buying pressure. Macro context shows a flattening yield curve (T10Y2Y at 2.1σ below trend), which is moderately supportive for defensives like CVS — a healthcare/pharmacy name that tends to benefit in risk-off or flattening environments. No reversal signals are evident from the data provided. With 295 minutes remaining (nearly a full session left), there is ample time for the move to continue or extend. However, the absence of a catalyst and the sub-2% magnitude temper conviction — this is ordinary momentum without a clear accelerant. Assigning a modest continuation probability above the threshold: the macro backdrop is a mild tailwind, time is sufficient, and there is no reason to expect a fade. Taking the trade at baseline momentum probability.
❖Jun 12, 10:02 AMnewsvia finnhub
Danaher Boosts Product Portfolio With the Acquisition of Masimo
DHR closes its $9.9B Masimo acquisition, adding AI-enabled patient-monitoring and sensor technologies to expand diagnostics solutions.
❖Jun 12, 9:49 AMnewsvia finnhub
5 Low Price-to-Book Stocks That Are Worth Buying in June
STNE, USNA, STRA, NEXA and CVS passed a low price-to-book screen, combining discounted valuations with projected long-term EPS growth.
❖Jun 12, 9:15 AMnewsvia finnhub
CVS Health Corporation (CVS) Hit a 52 Week High, Can the Run Continue?
CVS Health (CVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
❖Jun 12, 9:00 AMnewsvia finnhub
CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
❖Jun 12, 9:00 AMnewsvia finnhub
CVS Health To Deliver Faster, More Personalized Call Center Care for Millions of Members With Salesforce's Agentforce Health
Collaboration will improve call center experience for members and 1.5 million providers with AI agents Originally published on CVS Health Company Newsroom SAN FRANCISCO, CA AND WOONSOCKET, RI / ACCESS Newswire / June 12, 2026 / Salesforce (NYSE:CRM), ...
❖Jun 11, 11:18 AMnewsvia finnhub
Healthy Returns: CVS Health executives on reducing healthcare's biggest pain points
CVS Health execs discuss how the company is using AI and other technologies to reduce administrative burdens and deliver more proactive care experiences.
❖Jun 11, 11:15 AMnewsvia finnhub
Strong Performance Continues at DHR's Biotechnology Unit: What's Next?
Danaher is seeing strong Biotechnology growth as bioprocessing demand rises, with equipment orders up more than 30% and core revenue gains expected in 2026.
❖Jun 11, 10:43 AMnewsvia finnhub
CVS is Using Fluency to Close Enterprise AI Deployment Gap
CVS Health has partnered with Fluency, an Accel-backed AI platform, to scale autonomous agents from pilot to production. Fluency addresses enterprise AI's "deployment gap" by leveraging real operational data to identify automation opportunities, measure ROI, and embed AI effectively into existing workflows Photo Courtesy: Fluency SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- CVS Health is using Fluency, the Accel-backed enterprise AI deployment platform, to support deployment of autonomous AI
❖Jun 11, 9:00 AMnewsvia finnhub
Aetna Launches Aetna Mental Health on Demand To Provide Real Time Access to Care and Ongoing Support
HARTFORD, CT / ACCESS Newswire / June 11, 2026 / CVS Health In the initial launch, Aetna clinicians connected with members in just 13 seconds Originally published on CVS Health Company Newsroom Aetna®, a CVS Health® company (NYSE:CVS) today announced ...
❖Jun 11, 4:20 AMnewsvia finnhub
Patients Denied Care, Then Approved Later? Federal Watchdog Raises Medicare Advantage Concerns
Federal investigators found Medicare Advantage plans frequently denied requests for nursing and rehabilitation care, with many decisions later overturned on appeal.
❖Jun 10, 3:39 PMnewsvia finnhub
Musab Balbale Departs CVS Health; Zach Dennett Named Interim Merchandising Leader
After four years as chief merchandising officer, Balbale has departed CVS.
✓Jun 8, 6:04 PMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on CVS — 5-day return 7.13% with close above 20-day MA ($93.73). IV 29.4%. Sized 1 contract(s) at $3.60 premium.
!Jun 8, 7:01 AMsignal
Agent 6 — Options Momentum — insufficient_capital
▢Jun 7, 8:00 PMjournal
Agent 6 — Options Momentum opened long 100 @ $3.60
?Jun 3, 11:10 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CVS is up 1.85% today with no attributable headline, suggesting institutional flow or a sector rotation into defensive/healthcare names. The move is real but not outsized enough to signal exhaustion. Macro context shows a flattening yield curve (T10Y2Y at 2σ below trend), which historically supports defensive sectors like healthcare/pharma — a mild tailwind for CVS continuation. With 275 minutes remaining there is ample time for the move to extend. No reversal signals, no fade pattern, and no news-driven pump that would suggest a quick unwind. The absence of a catalyst is not a disqualifier per the framework. The setup is ordinary momentum with a supportive macro backdrop for defensives, warranting a modest above-neutral probability. No strong conviction for a large run, but the bias leans toward continuation into the close.
!Jun 3, 11:10 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CVS is up 1.85% today with no attributable headline, suggesting institutional flow or a sector rotation into defensive/healthcare names. The move is real but not outsized enough to signal exhaustion. Macro context shows a flattening yield curve (T10Y2Y at 2σ below trend), which historically supports defensive sectors like healthcare/pharma — a mild tailwind for CVS continuation. With 275 minutes remaining there is ample time for the move to extend. No reversal signals, no fade pattern, and no news-driven pump that would suggest a quick unwind. The absence of a catalyst is not a disqualifier per the framework. The setup is ordinary momentum with a supportive macro backdrop for defensives, warranting a modest above-neutral probability. No strong conviction for a large run, but the bias leans toward continuation into the close.
?Jun 3, 9:50 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CVS is up 1.79% with 355 minutes remaining — essentially a full session still ahead, which is ample time for continuation. The move is meaningful but below the 2-5% 'high conviction' threshold, so it reads as moderate momentum rather than a strong surge. No headlines are present to explain the move, which is neutral by the stated framework — absence of news does not disqualify. The macro context flags a compressed yield curve (T10Y2Y at 0.42, 2σ below trend), which is modestly supportive for defensives like CVS (a healthcare/pharmacy hybrid with defensive characteristics), though the bear-flattening framing is a mild headwind. With no reversal signals noted, no volume concerns flagged, and time remaining very generous, the base case is modest continuation. Probability stays in the lower tier of the continuation range given the sub-2% move size and lack of a clear catalyst to sustain buying pressure into the close.
!Jun 3, 9:50 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CVS is up 1.79% with 355 minutes remaining — essentially a full session still ahead, which is ample time for continuation. The move is meaningful but below the 2-5% 'high conviction' threshold, so it reads as moderate momentum rather than a strong surge. No headlines are present to explain the move, which is neutral by the stated framework — absence of news does not disqualify. The macro context flags a compressed yield curve (T10Y2Y at 0.42, 2σ below trend), which is modestly supportive for defensives like CVS (a healthcare/pharmacy hybrid with defensive characteristics), though the bear-flattening framing is a mild headwind. With no reversal signals noted, no volume concerns flagged, and time remaining very generous, the base case is modest continuation. Probability stays in the lower tier of the continuation range given the sub-2% move size and lack of a clear catalyst to sustain buying pressure into the close.
?May 20, 9:56 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CVS is up ~2% intraday with no headline catalyst, suggesting this is flow/positioning-driven rather than news-driven momentum. The move is meaningful but not extreme (2% sits at the lower end of the 2-5% significant range), and without a clear fundamental driver, the conviction behind continuation is moderate. Macro context shows elevated 10Y inflation expectations (~2.5σ above trend), which generally pressures long-duration sectors — but healthcare/pharmacy names like CVS are less sensitive to duration than utilities or growth tech, so this headwind is modest rather than decisive. With 350 minutes remaining (roughly the full afternoon session), there is ample time for the move to either extend or fade, which cuts both ways. No reversal signal is evident from the data provided. Base rate for intraday momentum continuation in a name like CVS, absent a fade signal, slightly favors continuation. Assigning a modest continuation probability above the 0.5 threshold given the time available and absence of a clear fade catalyst.
!May 20, 9:56 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CVS is up ~2% intraday with no headline catalyst, suggesting this is flow/positioning-driven rather than news-driven momentum. The move is meaningful but not extreme (2% sits at the lower end of the 2-5% significant range), and without a clear fundamental driver, the conviction behind continuation is moderate. Macro context shows elevated 10Y inflation expectations (~2.5σ above trend), which generally pressures long-duration sectors — but healthcare/pharmacy names like CVS are less sensitive to duration than utilities or growth tech, so this headwind is modest rather than decisive. With 350 minutes remaining (roughly the full afternoon session), there is ample time for the move to either extend or fade, which cuts both ways. No reversal signal is evident from the data provided. Base rate for intraday momentum continuation in a name like CVS, absent a fade signal, slightly favors continuation. Assigning a modest continuation probability above the 0.5 threshold given the time available and absence of a clear fade catalyst.
?May 19, 11:16 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CVS is down ~1.59% on no attributable news, which is a moderate but not outsized move. With 269 minutes remaining (~4.5 hours), there is ample time for the move to extend or reverse. The macro context shows elevated inflation expectations (T10YIE at 2.4σ above trend), which tends to pressure longer-duration and defensive/healthcare names like CVS modestly — a mild tailwind for continuation of the decline. However, without a catalyzing headline, the move may reflect broader sector rotation or light institutional flow rather than a conviction-driven thesis. The absence of a clear catalyst and the moderate magnitude (-1.59%, below the 2-5% high-conviction threshold) keep this in the borderline zone. No strong reversal signals visible. Default to slight continuation given macro headwind and momentum, but confidence is low — setting at the floor threshold.
!May 19, 11:16 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CVS is down ~1.59% on no attributable news, which is a moderate but not outsized move. With 269 minutes remaining (~4.5 hours), there is ample time for the move to extend or reverse. The macro context shows elevated inflation expectations (T10YIE at 2.4σ above trend), which tends to pressure longer-duration and defensive/healthcare names like CVS modestly — a mild tailwind for continuation of the decline. However, without a catalyzing headline, the move may reflect broader sector rotation or light institutional flow rather than a conviction-driven thesis. The absence of a clear catalyst and the moderate magnitude (-1.59%, below the 2-5% high-conviction threshold) keep this in the borderline zone. No strong reversal signals visible. Default to slight continuation given macro headwind and momentum, but confidence is low — setting at the floor threshold.
▣May 18, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 200 @ $2.61 (-$393.85)
Stop: premium $2.61 ≤ trailing floor $3.43 (peak $4.58 × 0.75)
✓May 14, 3:43 PMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on CVS — 5-day return 11.56% with close above 20-day MA ($84.17). IV 37.5%. Sized 2 contract(s) at $4.58 premium.
?May 14, 2:03 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CVS is down only 1.14% today, which is a modest move and not particularly compelling as a momentum signal on its own. There are no recent headlines to explain the move or suggest a fundamental catalyst driving further selling. The macro context (elevated 5Y inflation breakevens) is most reactive to Gold, Energy, and TIPS — not healthcare/pharmacy retail like CVS — so macro tailwinds for continuation are minimal. With 102 minutes remaining, there is ample time for a move to develop, but without a clear catalyst or strong magnitude, the move looks more like routine drift. The absence of news cuts both ways but the sub-1.5% move doesn't signal the kind of conviction flow that typically sustains into the close. Slight lean toward fade/consolidation rather than continuation, placing probability just below the 0.5 trigger threshold.
!May 14, 2:03 PMsignalseverity -0.01
Agent 7 — Day Trader — day_trade_skipped
CVS is down only 1.14% today, which is a modest move and not particularly compelling as a momentum signal on its own. There are no recent headlines to explain the move or suggest a fundamental catalyst driving further selling. The macro context (elevated 5Y inflation breakevens) is most reactive to Gold, Energy, and TIPS — not healthcare/pharmacy retail like CVS — so macro tailwinds for continuation are minimal. With 102 minutes remaining, there is ample time for a move to develop, but without a clear catalyst or strong magnitude, the move looks more like routine drift. The absence of news cuts both ways but the sub-1.5% move doesn't signal the kind of conviction flow that typically sustains into the close. Slight lean toward fade/consolidation rather than continuation, placing probability just below the 0.5 trigger threshold.
▢May 13, 8:00 PMjournal
Agent 6 — Options Momentum opened long 200 @ $4.58

← Back to dashboard